WP
MREO

WMS Partners’s Mereo BioPharma MREO Stock Holding History

WMS Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,642
Closed -$28K – 245
2020
Q3 		$28K Buy
+10,642
New +$31.1K 0.01% 232

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

WMS Partners's MREO Position: Q4 2020 in Review

WMS Partners sold out of Mereo BioPharma (MREO) in Q4 2020, closing a stake of 10,642 shares — an estimated $28K sold.

WMS Partners first reported a position in MREO in Q3 2020 and held it in 1 quarter. The position peaked at $28K in Q3 2020. 47 funds tracked by Wall St. Rank hold MREO as of Q4 2020.

  • WMS Partners reported no remaining Mereo BioPharma position as of Q4 2020 after selling out during the quarter.
  • WMS Partners sold 10,642 Mereo BioPharma shares in Q4 2020, an estimated $28K.
  • WMS Partners first reported a position in Mereo BioPharma in Q3 2020 and held it in 1 quarter.
  • WMS Partners's Mereo BioPharma position peaked at $28K in Q3 2020.
  • 47 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2020.

Based on WMS Partners's 13F filing for Q4 2020, filed 12 Feb 2021.